Graeme L Fraser
Inventor
Stats
- 15 US patents issued
- 21 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 15 US Patents Issued
- 21 US Applications Filed
- 163 Total Citation Count
- Oct 21, 2016 Most Recent Filing
- Jun 18, 2004 Earliest Filing
Work History
| Patent Owner | Applications Filed | Year |
|---|---|---|
| OGEDA SA | 2
1 1 | 2012
2014 2015 |
| TRANZYME PHARMA INC. | 1
| 2008
|
| OCERA THERAPEUTICS, INC. | 3
4 1 4 4 4 2 | 2004
2005 2006 2007 2008 2009 2011 |
Inventor Addresses
| Address | Duration |
|---|---|
| Bousval, BE | Sep 18, 14 - Sep 04, 18 |
| Québec, CA | Jan 13, 09 - May 28, 13 |
| Quebec, CA | Jan 25, 07 - Nov 24, 11 |
| Queber, CA | Jul 02, 09 - Jul 02, 09 |
| Rixensart, BE | Feb 28, 08 - Jun 21, 16 |
| Sherbrooke, CA | Feb 02, 06 - Aug 16, 11 |
Technology Profile
| Technology | Matters | |
|---|---|---|
| A01N: | PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF | 1 |
| A61K: | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | 17 |
| A61P: | THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS | 9 |
Patents / Publication
| Patents / Publication # | Year of Publication / Issued | Title | Citations |
|---|---|---|---|
| 10065961 | 2018 | Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof | 2 |
| 10065960 | 2018 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | 0 |
| 2018/0110,824 | 2018 | Macrocyclic Modulators of the Ghrelin Receptor | 0 |
| 9926325 | 2018 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | 0 |
| 9475814 | 2016 | -acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof | 6 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.